Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wells Fargo & Company from $260.00 to $262.00. They now have an "overweight" rating on the stock.
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $167.00 to $170.00. They now have an "overweight" rating on the stock.
Ascendis Pharma Reports First Quarter 2024 Financial Results [Yahoo! Finance]